Belen Garijo, the CEO of Merck KGaA, remains focused on oncology and immunology despite a 30% decrease in the company's stock since its peak in 2021.
The German drug-to-semiconductor group, under Garijo's leadership, has increased its investment in China and strengthened local supply chains, establishing itself as a significant player in the global market.
Merck KGaA operates in three distinct business units: life science, health care, and electronics. This company, which has a long history dating back to the 17th century, is separate from the US-based Merck & Co.
Garijo's approach demonstrates a commitment to long-term growth and innovation in the face of market fluctuations.